) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day up 1%. By the end of trading, Shire fell $1.16 (-1.3%) to $86.32 on light volume. Throughout the day, 212,410 shares of Shire exchanged hands as compared to its average daily volume of 565,100 shares. The stock ranged in price between $86.18-$86.84 after having opened the day at $86.60 as compared to the previous trading day's close of $87.48. Other company's within the Drugs industry that declined today were:

Chelsea Therapeutics International



), down 40.8%,

Tianyin Pharmaceutical



), down 8.1%,

IntelliPharmaCeutics International



), down 7.7%, and




), down 7.6%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals, Human Genetic Therapies, and Regenerative Medicine. Shire has a market cap of $16.2 billion and is part of the

health care

sector. The company has a P/E ratio of 18.5, equal to the average drugs industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Shares are down 15.8% year to date as of the close of trading on Monday. Currently there are 11 analysts that rate Shire a buy, no analysts rate it a sell, and five rate it a hold.

TheStreet Ratings rates Shire as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

On the positive front,




), up 25%,

Rexahn Pharmaceuticals



), up 20%,

Pernix Therapeutics Holdings



), up 18.7%, and




), up 14.7%, were all gainers within the drugs industry with

Celgene Corporation



) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech